Intravitreal bevacizumab for choroidal neovascularization and cystoid macular edema: a cost-effective treatment?

Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):270-1.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Choroidal Neovascularization / drug therapy
  • Choroidal Neovascularization / economics*
  • Cost-Benefit Analysis
  • Drug Costs
  • Health Care Costs
  • Humans
  • Injections
  • Macular Edema / drug therapy
  • Macular Edema / economics*
  • Vitreous Body

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab